• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    10/3/23 5:31:43 PM ET
    $ACON
    $ADTX
    $CPHI
    $FEMY
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • Sonendo (NYSE:SONX) shares increased by 51.4% to $0.48 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 649.4K shares, which is 1654.5 percent of its average volume over the last 100 days. The company's market cap stands at $25.5 million.
    • PureTech Health (NASDAQ:PRTC) stock increased by 17.26% to $23.7. The company's market cap stands at $650.6 million.
    • Phio Pharma (NASDAQ:PHIO) shares moved upwards by 12.83% to $1.67. The market value of their outstanding shares is at $3.7 million.
    • Histogen (NASDAQ:HSTO) shares rose 10.0% to $0.55. Trading volume for this security closed at 50.1K, accounting for 24.1% of its average full-day volume over the last 100 days. The company's market cap stands at $2.3 million.
    • China Pharma Holding (AMEX:CPHI) stock increased by 8.83% to $0.15. The market value of their outstanding shares is at $1.7 million.
    • Aditxt (NASDAQ:ADTX) shares increased by 8.69% to $12.5. The market value of their outstanding shares is at $2.9 million.

    Losers

    • MSP Recovery (NASDAQ:LIFW) shares declined by 15.9% to $0.21 during Tuesday's after-market session. MSP Recovery's trading volume hit 15.1 million shares by close, accounting for 43.5% of its average volume over the last 100 days. The market value of their outstanding shares is at $69.6 million.
    • Aclarion (NASDAQ:ACON) shares declined by 10.17% to $0.34. The company's market cap stands at $2.7 million.
    • Femasys (NASDAQ:FEMY) stock declined by 10.05% to $2.24. At the close, Femasys's trading volume reached 2.8 million shares. This is 26.1% of its average volume over the last 100 days. The market value of their outstanding shares is at $33.7 million.
    • Petros Pharma (NASDAQ:PTPI) stock fell 8.24% to $1.56. Trading volume for this security closed at 82.2K, accounting for 23.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.2 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) stock decreased by 7.72% to $0.36. Trading volume for this security closed at 7.9 million, accounting for 15.7% of its average full-day volume over the last 100 days. The company's market cap stands at $57.4 million.
    • Tenon Medical (NASDAQ:TNON) shares declined by 6.14% to $0.15. The company's market cap stands at $3.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $ADTX
    $CPHI
    $FEMY

    CompanyDatePrice TargetRatingAnalyst
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    Phio Pharmaceuticals Corp.
    $PHIO
    6/5/2025$14.00Buy
    H.C. Wainwright
    PureTech Health plc
    $PRTC
    9/9/2024$58.00 → $45.00Outperform
    Leerink Partners
    Sonendo Inc.
    $SONX
    3/12/2024Buy → Hold
    Stifel
    Sonendo Inc.
    $SONX
    1/31/2022$6.90Equal-Weight
    Morgan Stanley
    PureTech Health plc
    $PRTC
    1/7/2022$76.00 → $70.00Outperform
    SVB Leerink
    Sonendo Inc.
    $SONX
    11/23/2021$16.00Buy
    Stifel
    Sonendo Inc.
    $SONX
    11/23/2021$15.00Buy
    B of A Securities
    More analyst ratings

    $ACON
    $ADTX
    $CPHI
    $FEMY
    SEC Filings

    View All

    SEC Form DEF 14A filed by Femasys Inc.

    DEF 14A - FEMASYS INC (0001339005) (Filer)

    4/6/26 4:01:10 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form PRE 14A filed by Aclarion Inc.

    PRE 14A - Aclarion, Inc. (0001635077) (Filer)

    4/3/26 5:02:23 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by Aditxt Inc.

    DEF 14A - Aditxt, Inc. (0001726711) (Filer)

    4/3/26 4:37:32 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ADTX
    $CPHI
    $FEMY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video

    Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practiceNearly 100 Nociscans performed at The London Clinic, reflecting increasing utilization for evaluation of chronic low back pain BROOMFIELD, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of a new video featuring Mr. John Sutcliffe, Consultant Spinal Neurosu

    4/7/26 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

    Deupirfenidone 825 mg TID monotherapy significantly slowed lung function decline versus placebo at 26 weeks in people with idiopathic pulmonary fibrosis (adjusted mean FVC difference 91 mL; p=0.02), approaching the lung function change expected in normal, healthy aging First industry-sponsored IPF trial to include a current standard-of-care treatment as an active comparator in addition to a placebo arm, strengthening interpretation of efficacy and safety findings PureTech's Founded Entity, Celea Therapeutics, is working to complete a financing to enable the initiation of the Phase 3 SURPASS-IPF trial in the first half of 2026 PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" o

    4/2/26 8:19:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced positive topline data from portions of its ongoing Phase 1 proof-of-concept clinical trial evaluating GlyphAgoTM (SPT-320TM or Glyph Agomelatine). GlyphAgo is a novel, Glyphed oral prodrug of agomelatine in development for generalized anxiety disorder (GAD) and the second clinical-stage candidate from Seaport's pipeline. Based on the data shared today, Seaport announced plans to advance GlyphAgo into two parallel trials, a Phase 2a

    4/2/26 7:08:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ADTX
    $CPHI
    $FEMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Canning John Charles

    4 - FEMASYS INC (0001339005) (Issuer)

    4/1/26 5:31:32 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Canning John Charles

    3 - FEMASYS INC (0001339005) (Issuer)

    4/1/26 5:19:42 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Lee-Sepsick Kathy

    4 - FEMASYS INC (0001339005) (Issuer)

    3/27/26 5:00:26 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $ACON
    $ADTX
    $CPHI
    $FEMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Femasys with a new price target

    Laidlaw initiated coverage of Femasys with a rating of Buy and set a new price target of $6.50

    11/20/25 8:06:38 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright resumed coverage on Phio Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $14.00

    6/5/25 7:35:43 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners resumed coverage on PureTech Health plc with a new price target

    Leerink Partners resumed coverage of PureTech Health plc with a rating of Outperform and set a new price target of $45.00 from $58.00 previously

    9/9/24 7:42:36 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ADTX
    $CPHI
    $FEMY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    $ADTX
    $CPHI
    $FEMY
    Leadership Updates

    Live Leadership Updates

    View All

    Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

    ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of John Canning as Chief Operating Officer. Mr. Canning is an accomplished medical device executive with more than 25 years of experience leading global operations and technology organizations within complex medical device companies. He brings a track record of scaling organizations, advancing product pipelines, and driving operational excellence across key functions to support commercial growth and product adoption. Prior to joining

    4/1/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

    ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fel

    3/18/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $ACON
    $ADTX
    $CPHI
    $FEMY
    Financials

    Live finance-specific insights

    View All

    Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

    ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the year ended December 31, 2025 and provides a corporate update. Corporate Highlights from 4Q 2025 to date Initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc, advancing toward U.S. approval.Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, strengthening leadership and strategic oversight.FemBloc permanent birth control system achieved certification under the Medical Device Single Au

    3/31/26 4:05:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

    BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (NASDAQ:ACON, ACONW)) ("Aclarion" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan is effective immediately and expires in one year. The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to

    3/19/26 9:25:40 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ADTX
    $CPHI
    $FEMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/14/24 5:17:37 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sonendo Inc.

    SC 13G/A - Sonendo, Inc. (0001407973) (Subject)

    11/14/24 4:40:34 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care